Logo

American Heart Association

  131
  0


Final ID:

Moving the Needle on Lipid Management: Getting to Goal

  • Schwartz, Gregory  ( VA EASTERN COLORADO HEALTHCARE SYST , Aurora , Colorado , United States )
  • Author Disclosures:
    Gregory Schwartz: DO have relevant financial relationships ; Researcher:AstraZeneca:Active (exists now) ; Researcher:Silence Therapeutics:Active (exists now) ; Researcher:Sanofi:Active (exists now)
Meeting Info:

Scientific Sessions 2025

2025

New Orleans, Louisiana

Session Info:

Lipid Therapies: Translation to Implementation

Monday, 11/10/2025 , 03:15PM - 04:30PM

Featured Science

More abstracts on this topic:
Dose-Dependent and Sustained Reduction in Lipoprotein(a) levels after single-dose of Kylo-11, a LPA-targeted Small Interfering RNA, in Healthy Volunteers: A First-in-Human Phase I Study

Du Xiaolin, Zhou Luping, Luo Jingying, Gu Yumei, Liu Ziyang, Zhang Qinsheng, Guan Tao, Cui Kunyuan, Yong Xiaolan

SHR-1918, an Angiopoietin-Like 3 Antibody, in Patients With Suboptimally Controlled Hyperlipidemia

Zhong Zhixiong, Zhu Min, Zhu Ying, Zhang Jing, Dan Zhu, Pei Hanjun, Wu Wanling, Huang Rongjie, Yin Delu, Gao Xiaohong, Lv Chao

More abstracts from these authors:
The Effect of PCSK9 Inhibition With Alirocumab in Patients With Probable Familial Hypercholesterolemia or Type III Hyperlipoproteinemia: Results from the ODYSSEY OUTCOMES Trial

Geba Gregory, Bittner Vera, Bhatt Deepak, Szarek Michael, Schwartz Gregory, Steg Philippe, Fazio Sergio, Mohammadi Kusha, Damask Amy, Paulding Charles, Lotta Luca, Hindy George, Pordy Robert, Manvelian Garen, Shapiro Michael

Discussant: META-AF

Potpara Tatjana, Chung Mina, Schwartz Gregory

You have to be authorized to contact abstract author. Please, Login
Not Available